These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35243952)

  • 61. Smoking history and pulmonary arterial hypertension: Demographics, onset, and outcomes.
    Frost AE; Zhao C; Farber HW; Benza R; Yen J; Selej M; Elliott CG
    J Heart Lung Transplant; 2023 Mar; 42(3):377-389. PubMed ID: 36404264
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The role of serial right heart catheterization in risk stratification and management of pulmonary arterial hypertension.
    Sharma D; Shah RJ; Sreenivasan J; Kafle P; Gupta R; Levine A; Lanier GM; Aronow WS
    Expert Rev Cardiovasc Ther; 2022 Jul; 20(7):543-547. PubMed ID: 35726644
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mixed Venous Oxygen Saturation Is a Better Prognosticator Than Cardiac Index in Pulmonary Arterial Hypertension.
    Khirfan G; Almoushref A; Naal T; Abuhalimeh B; Dweik RA; Heresi GA; Tonelli AR
    Chest; 2020 Dec; 158(6):2546-2555. PubMed ID: 32629034
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Survival of Left-to-Right Shunt Repair in Children with Pulmonary Arterial Hypertension at a Tertiary Hospital in a Low-to-Middle-Income Country.
    Arafuri N; Murni IK; Idris NS; Uiterwaal CSPM; Savitri AI; Nugroho S; Noormanto N
    Glob Heart; 2021 Apr; 16(1):25. PubMed ID: 34040938
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Stem cell therapy for pulmonary arterial hypertension: An update.
    Sun QW; Sun Z
    J Heart Lung Transplant; 2022 Jun; 41(6):692-703. PubMed ID: 35341679
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Initial dual oral combination therapy in pulmonary arterial hypertension.
    Sitbon O; Sattler C; Bertoletti L; Savale L; Cottin V; Jaïs X; De Groote P; Chaouat A; Chabannes C; Bergot E; Bouvaist H; Dauphin C; Bourdin A; Bauer F; Montani D; Humbert M; Simonneau G
    Eur Respir J; 2016 Jun; 47(6):1727-36. PubMed ID: 26989105
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Healthcare burden of pulmonary hypertension owing to lung disease and/or hypoxia.
    Heresi GA; Platt DM; Wang W; Divers CH; Joish VN; Teal SA; Yu JS
    BMC Pulm Med; 2017 Apr; 17(1):58. PubMed ID: 28399914
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry.
    Kolaitis NA; Zamanian RT; de Jesus Perez VA; Badesch DB; Benza RL; Burger CD; Chakinala MM; Elwing JM; Feldman J; Lammi MR; Mathai SC; McConnell JW; Presberg KW; Robinson JC; Sager J; Shlobin OA; Simon MA; Kawut SM; Glidden DV; Singer JP; De Marco T;
    Ann Am Thorac Soc; 2021 Apr; 18(4):613-622. PubMed ID: 33064950
    [No Abstract]   [Full Text] [Related]  

  • 69. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management.
    Barst RJ; McGoon MD; Elliott CG; Foreman AJ; Miller DP; Ivy DD
    Circulation; 2012 Jan; 125(1):113-22. PubMed ID: 22086881
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Performance of screening algorithms in systemic sclerosis-related pulmonary arterial hypertension: a systematic review.
    Thakkar V; Stevens WM; Moore OA; Nikpour M
    Intern Med J; 2013 Jul; 43(7):751-60. PubMed ID: 23611651
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Haemodynamic effects of PAH-targeted therapies in pulmonary hypertension due to lung disease: A systematic review and meta-analysis.
    Farmakis IT; Vazakidis P; Doundoulakis I; Arvanitaki A; Zafeiropoulos S; Boutou A; Karvounis H; Giannakoulas G
    Pulm Pharmacol Ther; 2021 Jun; 68():102036. PubMed ID: 33979684
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology.
    Montani D; Achouh L; Dorfmüller P; Le Pavec J; Sztrymf B; Tchérakian C; Rabiller A; Haque R; Sitbon O; Jaïs X; Dartevelle P; Maître S; Capron F; Musset D; Simonneau G; Humbert M
    Medicine (Baltimore); 2008 Jul; 87(4):220-233. PubMed ID: 18626305
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension.
    Guillén-Del-Castillo A; Meseguer ML; Fonollosa-Pla V; Giménez BS; Colunga-Argüelles D; Revilla-López E; Rubio-Rivas M; Ropero MJC; Argibay A; Barberá JA; Salas XP; Meñaca AM; Vuelta ABM; Padrón AL; Comet LS; Morera JAD; González-Echávarri C; Mombiela T; Ortego-Centeno N; González MM; Tolosa-Vilella C; Blanco I; Subías PE; Simeón-Aznar CP; ;
    Sci Rep; 2022 Mar; 12(1):5289. PubMed ID: 35347225
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension.
    Takatsuki S; Rosenzweig EB; Zuckerman W; Brady D; Calderbank M; Ivy DD
    Pediatr Pulmonol; 2013 Jan; 48(1):27-34. PubMed ID: 22511577
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up.
    Xanthouli P; Koegler M; Marra AM; Benjamin N; Fischer L; Eichstaedt CA; Harutyunova S; Nagel C; Grünig E; Egenlauf B
    Respir Res; 2020 May; 21(1):127. PubMed ID: 32448256
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Efficacy of fenestrated atrial septal defect occulders on pulmonary hypertension dogs].
    Yang LF; Chen DD; Wang GF; Long YL; Jin QC; Kong DH; Pan WZ; Guan LH; Zhou DX; Ge JB
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Feb; 50(2):166-171. PubMed ID: 35172462
    [No Abstract]   [Full Text] [Related]  

  • 77. Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study.
    Hascoet S; Fournier E; Jaïs X; Le Gloan L; Dauphin C; Houeijeh A; Godart F; Iriart X; Richard A; Radojevic J; Amedro P; Bosser G; Souletie N; Bernard Y; Moceri P; Bouvaist H; Mauran P; Barre E; Basquin A; Karsenty C; Bonnet D; Iserin L; Sitbon O; Petit J; Fadel E; Humbert M; Ladouceur M
    Arch Cardiovasc Dis; 2017 May; 110(5):303-316. PubMed ID: 28286190
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinical Study of Acute Vasoreactivity Testing in Patients with Chronic Thromboembolic Pulmonary Hypertension.
    Xu QX; Yang YH; Geng J; Zhai ZG; Gong JN; Li JF; Tang X; Wang C
    Chin Med J (Engl); 2017 Feb; 130(4):382-391. PubMed ID: 28218209
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Baseline history of patients using selexipag for pulmonary arterial hypertension.
    Highland KB; Hull M; Pruett J; Elliott C; Tsang Y; Drake W
    Ther Adv Respir Dis; 2019; 13():1753466619843774. PubMed ID: 30983530
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.
    Vachiéry JL; Galiè N; Barberá JA; Frost AE; Ghofrani HA; Hoeper MM; McLaughlin VV; Peacock AJ; Simonneau G; Blair C; Miller KL; Langley J; Rubin LJ;
    J Heart Lung Transplant; 2019 Feb; 38(2):194-202. PubMed ID: 30522722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.